Hormonal
GLP-1 receptor agonists (GLP-1RAS) significantly reduce body weight and improve glucose tolerance in prediabetic patients, offering a potent alternative to metformin, particularly for those with obesity.
GLP-1 receptor agonists (like semaglutide or liraglutide) are injectable medications that significantly reduce weight and improve blood sugar in prediabetes. They are particularly effective for overweight individuals. Side effects like nausea are common initially. They are more potent than metformin for weight loss but require injection.
GLP-1RAS notably aids the restoration of glucose homeostasis, improves islet function, enhances insulin sensitivity, and controls body weight. ... Significant weight loss and improved blood sugar
Why this rating
Supported by multiple clinical trials showing significant weight loss and HbA1c reduction.
Source
Metabolic disorders in prediabetes: From mechanisms to therapeutic management
Wen-Xin Ping et al. · World Journal of Diabetes · 2024
DOI 10.4239/wjd.v15.i3.361
More from this paper
- Metformin is the most effective pharmacological intervention for preventing type 2 diabetes in prediabetic patients, significantly reducing diabetes incidence and improving glucose tolerance compared to lifestyle interventions alone.Good
- SGLT2 inhibitors reduce blood glucose and body weight in prediabetic patients by increasing urinary glucose excretion, effectively delaying diabetes development.Good
- Vitamin D supplementation (≥ 1000 IU/day) reduces the risk of developing diabetes in individuals with prediabetes by improving insulin sensitivity and beta-cell function.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →